.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Slow, Costly Process Stymies Generic Biotech Drugs

March 6, 2012

One of the pledges of the Obama administration's healthcare overhaul was to enable cheaper copies of expensive biotech drugs, but the savings may not be as deep or come as quickly as hoped.

Healthcare companies and industry experts say questions over how the market will work and the specter of patent litigation mean robust competition for generic biotech drugs might wait until the end of the decade. The regulatory requirements - which could force drugmakers to spend more money on testing - could mean eventual cost savings for payers of as little as 10 or 20 percent per treatment.

Read the full story:

http://hcp.lv/zX9DTK

Source: Reuters